ArticleLeukemia2024
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
Abstract readLetter
In one paragraph
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Guideline
- 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.Leukemia · 2025Guideline
- A design approach for bitopic kinase inhibitors.Nature · 2026Article
- The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia.Neoplasia (New York, N.Y.) · 2026Article
- Prognostic factors in chronic myeloid leukemia: at diagnosis and for treatment-free remission.Haematologica · 2026Review
- Intrinsic cellular resistance to BCR::ABL1 inhibitors.Haematologica · 2026Review
- Is there a best frontline therapy in chronic myeloid leukemia?Haematologica · 2026Review
- Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1.Genome medicine · 2026Article
- Article
- Impact of insertion/deletion mutations affecting theHaematologica · 2026Article
- Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.Current hematologic malignancy reports · 2026Review
- Chronic Myeloid Leukemia: Historical Perspective, Pathophysiology, and Treatment Advances.Acta haematologica · 2026Review
- Alternative splicing in cancer drug resistance: Mechanisms and therapeutic prospects (Review).Oncology reports · 2026Review
- Primary asciminib resistance in a chronic myeloid leukemia patient with the atypicalHaematologica · 2026Article
- Dual-Driver Myeloproliferative Neoplasm: Concurrent p190Case reports in hematology · 2026Article
- Resistance to Allosteric Inhibitors.Journal of molecular biology · 2025Review
- Asciminib for Philadelphia chromosome-positive leukemias.Haematologica · 2025Review
- Activity of STAMP inhibitors inBlood neoplasia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Ariel Leyte-VidalDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.
RosaAnna DeFilippisDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.ORCID 0009-0006-1365-235X
Ian R OuthwaiteDepartment of Pharmacological Sciences, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.ORCID 0000-0003-2037-3261
Isabelle KwanDepartment of Pharmacological Sciences, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.
Ji Young LeeLaufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY, 11794, USA.ORCID 0000-0002-1491-6963
Carlyn LeavittDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.
Kaeli B MillerDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.
Delphine ReaAdult Hematology Department, Hôpital Saint-Louis, Paris, France.ORCID 0000-0001-5379-7461
Aziz M RangwalaDepartment of Pharmacological Sciences, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.ORCID 0000-0003-3556-7931
Kevin LouDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, 94158, USA.
Suhana PatelDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.
Ailin AlvarezDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.
Kevan M ShokatDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, 94158, USA.
Ivet BaharLaufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY, 11794, USA.
Markus A SeeligerDepartment of Pharmacological Sciences, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.ORCID 0000-0003-0990-1756
Neil P ShahDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA. neil.shah@ucsf.edu.ORCID 0000-0003-4398-3388
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008444 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI FROHMAN, MICHAEL A. · 1992 to 2024
$12.6MDynamics of Ligand Binding and Protein Kinase Regulation_RenewalR35GM119437 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Markus A Seeliger · 2016 to 2026
$6.5MResearch Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1MChemical Biology Training InterfaceT32GM136572 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI ELIZABETH M BOON, Jessica Chuang Seeliger · 2020 to 2026
$2.9MToward a Deeper Understanding of Allostery and Allotargeting by Computational ApproachesR01GM139297 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ivet Bahar · 2021 to 2026
$2.8MBrain-Restricted Kinase Inhibition with Binary PharmacologyR01CA281984 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Qi Wen Fan, KEVAN M SHOKAT · 2024 to 2026
$2.0MRobotic assay platformS10OD028478 · OD · STATE UNIVERSITY NEW YORK STONY BROOK · PI SEELIGER, MARKUS A · 2020 to 2020
$173kMaximizing Selective Inhibition of Clinically Observed MET MutantsF30CA281272 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI Ian Outhwaite · 2024 to 2026
$151kAmerican Society of Hematology (ASH) A141755NCI NIH HHS F30 CA281272NCI NIH HHS R01 CA281984NIGMS NIH HHS R01 GM139297NIGMS NIH HHS R35 GM119437NIGMS NIH HHS T32 GM008444NIGMS NIH HHS T32 GM136572NIGMS NIH HHS T32 GM145460NIH HHS S10 OD028478U.S. Department of Health & Human Services | National Institutes of Health (NIH) 1R01CA281984U.S. Department of Health & Human Services | National Institutes of Health (NIH) NIH T32GM136572U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01GM139297U.S. Department of Health & Human Services | National Institutes of Health (NIH) R35GM119437U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32GM008444
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug Resistance, NeoplasmExonsFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNiacinamideProtein ConformationProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrazolessrc Homology DomainsABL1 protein, humanasciminibBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablNiacinamideProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.